by Cal Strode | Jul 12, 2023
In 2017, Signals’ blog carnival focused on Right to Try (RTT) legislation – laws that allow patients with life-threatening conditions to ask drugmakers for medicines that have cleared some testing hurdles, but still haven’t been approved by the U.S. Food and Drug...
by Peace Chukwu | Jul 6, 2023
Imagine slowly losing control of your body and the muscles necessary to live healthily, until you eventually lose your ability to breathe. This disease is known as Amyotrophic lateral sclerosis, or ALS, and is caused by the degeneration of motor neurons that send...
by Kevin Robb | Jun 29, 2023
Mesenchymal stromal cells (MSCs) have been at the front line of cell therapy and regenerative medicine efforts for decades. Investigators hotly pursued MSCs as prospective cell therapies for a wide range of diseases, but enthusiasts were left wanting when several...
by Sara M. Nolte | Jun 21, 2023
In addition to showers, flowers and warmer weather, this spring also brought renewed hope for patients with hematological malignancies undergoing stem cell transplants (SCTs) in the form of the approval of Gamida Cell’s Omisirge® (omidubicel). This cell-based therapy...
by Stacey Johnson | Jun 16, 2023
The definition of a rare disease in the U.S. is under 200,000 patients. The 10 per cent of Americans living with a rare disease is equivalent to 30 million people. Put another way, that is close to the entire population of Canada (at 39 million). There are 7,000 –...
by Stacey Johnson | Jun 9, 2023
Courtney Horvath, PhD, is a board certified toxicologist who knows firsthand about toxicity in pediatric oncology treatments. Her son, Colby, was diagnosed with lymphoma at the age of eight, in March 2020, and she has since become an advocate for better cancer...
Comments